Same-day hospital discharge (SDD) is safe in selected patients after transcatheter aortic valve implantation (TAVI).

In patients with symptomatic severe aortic stenosis at intermediate or higher surgical risk, CoreValve or Evolut transcatheter aortic valve implantation (TAVI) was associated with a lower 5-year ...

The US Food and Drug Administration has expanded its indications for the Evolut family of valves (Medtronic) to include redo TAVI inpatients at high risk for surgery. The approval now includes use for ...

With careful selection, same-day hospital discharge was found to be feasible and safe in around one-fifth of patients undergoing transcatheter aortic valve implantation in a study presented at the ...

Read more about how transcatheter aortic valve implantation results in a higher risk of mortality and stroke compared with surgical replacement.

While there is no significant difference in the risk of all-cause mortality or disabling stroke in midterm follow-up of the Evolut Low Risk trial, new findings with the self-expanding bioprosthesis ...

After receiving a green light earlier this year from the FDA, Medtronic has now collected a European approval for the latest version of its transcatheter aortic valve replacement implant. Compared to ...

A new study published in The Annals of Thoracic Surgery, has identified early hemodynamic valve deterioration (HVD) in more than 6% of patients just one year after undergoing transcatheter aortic ...

The benefit of percutaneous coronary intervention (PCI) in patients with stable coronary artery disease and severe aortic stenosis who are undergoing transcatheter aortic-valve implantation (TAVI) ...

Aug 1 (Reuters) - Medtronic Plc : * CoreValve Evolut R System TAVI to receive CE mark for intermediate risk aortic stenosis patients Source text for Eikon: Further company coverage: ...